Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

5.365 +0.235 (+4.58%)
Streaming Delayed Price Updated: 11:43 AM EST, Nov 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown
Via Stocktwits
Earnings Scheduled For November 5, 2025
 
Via Benzinga
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
 
Via Benzinga
This Southwest Gas Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday
 
Via Benzinga
This Oddity Tech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Earnings Outlook For Vir Biotechnology
 
Via Benzinga
5 Analysts Have This To Say About Vir Biotechnology
 
Via Benzinga
7 Analysts Have This To Say About Vir Biotechnology
 
Via Benzinga
This Guess Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
 
Via Benzinga
This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Vir (VIR) Q2 Revenue Drops 61%
Via The Motley Fool
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Earnings Scheduled For February 26, 2025
 
Via Benzinga
Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment
The company is working to engage the immune system to attack cancer cells. 
Via Investor's Business Daily
Where Vir Biotechnology Stands With Analysts
 
Via Benzinga
Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
 
Via Benzinga
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies. 
Via Benzinga
AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels. 
Via Investor's Business Daily
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
Vir Biotechnology's Phase 2 study on hepatitis B treatments shows promising antigen loss rates, with up to 46% achieving seroclearance in key regimens. 
Via Benzinga
What You Missed On Wall Street This Past Friday
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.